Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) ("SCT" or the "Company") a life
sciences development company of stem cell-related therapeutics, today announced
a reminder that a Special Meeting of Shareholders will be held in the Offices of
McCarthy Tetrault LLP, Toronto Dominion Bank Tower, 66 Wellington Street West,
53rd Floor, J.J. Robinette Boardroom, Toronto, ON M5K 1E6, on Thursday, December
20, 2012, at 10:00 a.m. Eastern Time. 


The Special Meeting will consider resolutions set forth in the Management
Information Circular dated November 22, 2012, accessible on SEDAR at
www.sedar.com. Interested shareholders, unable to attend the meeting in person,
can listen to the proceedings live via conference call.


Stem Cell Therapeutics has provided a corporate update for its shareholders,
which is available on the Investors page of the Company's website:
www.stemcellthera.com. Mr. David Allan, Executive Chairman of Stem Cell
Therapeutics will also host a question and answer session following the Special
Meeting. Conference call participants wishing to ask a question will be
instructed by the operator on how to do so at this time.


Details to listen live:



Date:               Thursday, December 20, 2012                             
Time:               10:00 a.m. ET                                           
Dial-in Number:     (647) 427-7450 or (888) 231-8191                        
Taped Replay:       (416) 849-0833 or (855) 859-2056                        
Reference Number:   77609672                                                



About Stem Cell Therapeutics

Stem Cell Therapeutics Corp. (TSX VENTURE:SSS) is a Canadian commercialization
receptor company in the business of developing stem cell-based therapeutics
through partnerships with research institutions or technology transfer
organizations. The Company's corporate objectives include the analysis and
acquisition of additional stem cell-related development opportunities and
securing capital for the advancement of the licensed or acquired products. In
October 2012 SCT became a member of the 20-member Centre for Commercialization
of Regenerative Medicine ("CCRM") consortium. SCT has extensive expertise and
experience in the stem cell biotechnology sector based on the intellectual
property of Dr. Samuel Weiss in stem cell research. SCT proposes to build upon
the foundational technologies by acquiring additional early-stage clinical or
late-stage preclinical candidates. SCT's Traumatic Brain Injury product,
NTx(R)-428, is currently in a Phase II clinical trial. For more information,
visit: www.stemcellthera.com.


Caution Regarding Forward-Looking Information: 

Certain statements contained in this press release constitute forward-looking
information within the meaning of applicable Canadian provincial securities
legislation (collectively, the "forward-looking statements"). These
forward-looking statements relate to, among other things, SCT's objectives,
goals, targets, strategies, intentions, plans, beliefs, estimates and outlook,
and can, in some cases, be identified by the use of words such as "believe,"
"anticipate," "expect," "intend," "plan," "will," "may" and other similar
expressions. In addition, any statements that refer to expectations, projections
or other characterizations of future events or circumstances are forward-looking
statements. These statements reflect management's current beliefs and are based
on information currently available to management. Certain material factors or
assumptions are applied in making forward-looking statements, and actual results
may differ materially from those expressed or implied in such statements.
Important factors that could cause actual results to differ materially from
these expectations include, among other things: uncertainties and risks related
to, the availability of capital, changes in capital markets, uncertainties
related to clinical trials and product development, rapid technological change,
uncertainties related to forecasts, competition, potential product liability,
unproven markets for technologies in development, the cost and supply of raw
materials, management of growth, effects of payers'' willingness to pay for
products, risks related to regulatory matters and risks related to intellectual
property matters. Additional information about these factors and about the
material factors or assumptions underlying such forward-looking statements may
be found in the body of this news release, as well as under the heading "Risk
Factors" contained in SCT's 2010 annual information form. SCT cautions that the
foregoing list of important factors that may affect future results is not
exhaustive. 


When relying on SCT's forward-looking statements to make decisions with respect
to SCT, investors and others should carefully consider the foregoing factors and
other uncertainties and potential events. Such forward-looking statements are
based on a number of estimates and assumptions which may prove to be incorrect,
including, but not limited to, assumptions regarding the availability of
financing for research and development companies in addition to general business
and economic conditions. These risks and uncertainties should be considered
carefully and investors and others should not place undue reliance on the
forward-looking statements. Although the forward-looking statements contained in
this press release are based upon what management believes to be reasonable
assumptions, SCT cannot provide assurance that actual results will be consistent
with these forward-looking statements. SCT undertakes no obligation to update or
revise any forward-looking statement. 


FOR FURTHER INFORMATION PLEASE CONTACT: 
Stem Cell Therapeutics Corp.
David Allan
Executive Chairman
DAllan@StemCellThera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more Sunvest Minerals Corp Charts.